Product NDC: | 63323-317 |
Proprietary Name: | Granisetron |
Non Proprietary Name: | GRANISETRON HYDROCHLORIDE |
Active Ingredient(s): | .1 mg/mL & nbsp; GRANISETRON HYDROCHLORIDE |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 63323-317 |
Labeler Name: | Fresenius Kabi USA, LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA078522 |
Marketing Category: | ANDA |
Start Marketing Date: | 20091120 |
Package NDC: | 63323-317-01 |
Package Description: | 10 VIAL in 1 TRAY (63323-317-01) > 1 mL in 1 VIAL |
NDC Code | 63323-317-01 |
Proprietary Name | Granisetron |
Package Description | 10 VIAL in 1 TRAY (63323-317-01) > 1 mL in 1 VIAL |
Product NDC | 63323-317 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | GRANISETRON HYDROCHLORIDE |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20091120 |
Marketing Category Name | ANDA |
Labeler Name | Fresenius Kabi USA, LLC |
Substance Name | GRANISETRON HYDROCHLORIDE |
Strength Number | .1 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Serotonin 3 Receptor Antagonists [MoA],Serotonin-3 Receptor Antagonist [EPC] |